Heated chemo during surgery may curb return of rare uterine cancer
NCT ID NCT04727242
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested whether giving heated chemotherapy directly into the abdomen during surgery, followed by standard chemo, could help prevent uterine leiomyosarcoma from coming back. Seventeen women with locally recurrent cancer took part. The goal was to see if this combined approach improves how long patients live without the cancer progressing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- gemcitabine and dacarbazine
- What this could lead to
- If it works, this approach could lower the chance of uterine leiomyosarcoma coming back after surgery.
- What could go wrong
- This is a small, early-phase study with only 17 participants, so results may not apply to everyone. Heated chemotherapy also carries risks like infection and side effects from the drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LMS - LEIOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stanford University
Stanford, California, 94305, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.